Form 4 for VKTX Viking Therapeutics, Inc.
Accepted 2023-04-13 00:00:00 ET · period of report 2023-04-11 · accession 0001209191-23-024227 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-04-13 | 2023-04-11+ | VKTX | ZANTE GREG | CFO | M - OptEx | $5.57 | +97.8K | 152.5K | +179% | +$544.8K |
| DM | 2023-04-13 | 2023-04-11+ | VKTX | ZANTE GREG | CFO | S - Sale+OE | $18.00 | -97.8K | 149.3K | -40% | -$1.76M |
| DM | 2023-04-13 | 2023-04-11+ | VKTX | ZANTE GREG | CFO | M - OptEx | $0.00 | -97.8K | 16.8K | -85% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, par value $0.00001 per share | 2023-04-12 | M | A | 37,447 | $5.80 | 186,726 | D | — | — | |
| 2 | Common | Common Stock, par value $0.00001 per share | 2023-04-12 | M | A | 4,097 | $7.77 | 190,823 | D | — | — | |
| 3 | Common | Common Stock, par value $0.00001 per share | 2023-04-12 | S | D | 41,544 | $18.00 | 149,279 | D | — | — | |
| 4 | Common | Common Stock, par value $0.00001 per share | 2023-04-11 | S | D | 56,295 | $18.00 | 149,279 | D | — | — | |
| 5 | Common | Common Stock, par value $0.00001 per share | 2023-04-11 | M | A | 14,553 | $5.80 | 205,574 | D | — | — | |
| 6 | Common | Common Stock, par value $0.00001 per share | 2023-04-11 | M | A | 30,000 | $4.88 | 191,021 | D | — | — | |
| 7 | Common | Common Stock, par value $0.00001 per share | 2023-04-11 | M | A | 8,500 | $4.68 | 161,021 | D | — | — | |
| 8 | Common | Common Stock, par value $0.00001 per share | 2023-04-11 | M | A | 3,242 | $7.77 | 152,521 | D | — | — | |
| 9 | Derivative | Stock Option (right to buy | 2023-04-11 | M | D | 8,500 | $0.00 | 8,500 | D | $4.68 · 2021-03-31 to 2030-03-31 | 8,500 Common Stock | (F2) 25% of the shares subject to the option vested or will vest on each one year anniversary of the grant date. |
| 10 | Derivative | Stock Option (right to buy) | 2023-04-12 | M | D | 4,097 | $0.00 | 12,750 | D | $7.77 · 2021-01-03 to 2030-01-03 | 4,097 Common Stock | (F2) 25% of the shares subject to the option vested or will vest on each one year anniversary of the grant date. |
| 11 | Derivative | Stock Option (right to buy | 2023-04-12 | M | D | 37,447 | $0.00 | 26,000 | D | $5.80 · 2022-01-04 to 2031-01-04 | 37,447 Common Stock | (F4) One-third of the shares subject to the option vested or will vest on each one year anniversary of the grant date. |
| 12 | Derivative | Stock Option (right to buy | 2023-04-11 | M | D | 14,553 | $0.00 | 63,447 | D | $5.80 · 2022-01-04 to 2031-01-04 | 14,553 Common Stock | (F4) One-third of the shares subject to the option vested or will vest on each one year anniversary of the grant date. |
| 13 | Derivative | Stock Option (right to buy | 2023-04-11 | M | D | 30,000 | $0.00 | 90,000 | D | $4.88 · 2023-01-03 to 2032-01-03 | 30,000 Common Stock | (F2) 25% of the shares subject to the option vested or will vest on each one year anniversary of the grant date. |
| 14 | Derivative | Stock Option (right to buy) | 2023-04-11 | M | D | 3,242 | $0.00 | 16,847 | D | $7.77 · 2021-01-03 to 2030-01-03 | 3,242 Common Stock | (F3) The Form 4 filed by the Reporting Person on April 3, 2023 reporting, among other things, the exercise of 30,911 shares subject to this option on April 3, 2023 inadvertently indicated that there were 0 shares remaining subject to this option after such exercise. That Form 4 should have reflected that there were 20,089 shares remaining subject to this option after such exercise and the balance has been adjusted accordingly in this Form 4. (F2) 25% of the shares subject to the option vested or will vest on each one year anniversary of the grant date. |